AI Article Synopsis
- - There is limited data on the effectiveness and safety of using intravenous thrombolysis with rtPA for treating acute ischemic stroke (AIS) in patients who also have brain tumors.
- - Most existing information comes from a few case reports, making it hard to draw strong conclusions about this treatment in such patients.
- - This report describes a successful case of IV thrombolysis with rtPA in a patient with oligodendroglioma who was undergoing treatment with bevacizumab, noting no bleeding complications, and also reviews other published cases on this topic.
Article Abstract
Data on efficacy and safety of intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rtPA) in patients with acute ischemic stroke (AIS) and intracranial neoplasm are lacking. To date, only a handful of case reports have been published in the literature addressing the administration of IV rtPA to patients with AIS and coexisting brain neoplasms. We present the case of successful IV thrombolysis with rtPA for AIS in a patient with oligodendroglioma on bevacizumab without hemorrhagic complications. We summarize the published cases of thrombolysis in AIS in patients with intracranial neoplasms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2013.07.031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systemic intravenous thrombolysis and spinal stroke: a case report and review of the literature.
BMJ Neurol Open
December 2024
Department of Neurology, Lady Davis Carmel Medical Center, Haifa, Israel.
Background: Spinal cord infarction (SCI) is associated with poor clinical outcome. Intravenous thrombolysis (IVT) is a well-established treatment for cerebral ischaemic stroke. However, its efficacy in SCI is unknown.
View Article and Find Full Text PDFGeo-Spatial Analysis of Acute Ischemic Stroke Reperfusion Treatment in India: An Assessment of Distribution and Access to Centers.
Int J Stroke
December 2024
PN Sylaja, DM, Professor and Head of Neurology, SCTIMST, Thiruvananthapuram, Kerala, India.
Background: Stroke is a leading cause of global mortality and disability, with a disproportionately high burden in low- and middle-income countries. Access to intravenous thrombolysis (IVT) and endovascular treatment (EVT) remains extremely limited.
Aims: We evaluated the spatial distribution and geographic accessibility of stroke centers in India.
Intracoronary Tissue Plasminogen Activator Therapy to Treat Thrombotic Occlusion of a Giant Coronary Aneurysm in Early Kawasaki Disease.
Catheter Cardiovasc Interv
December 2024
Department of Fetal, Neonatal and Cardiovascular Sciences, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Kawasaki Disease (KD) is a systemic vasculitis that can lead to coronary artery aneurysms (CAA) in up to 10% of treated cases, significantly increasing the risk of thrombosis and acute myocardial infarction (AMI). While thrombolytic therapy is commonly used in adult coronary syndromes, its application in pediatric KD remains poorly studied. We report a 9-month-old infant with KD and giant CAA complicated by a subocclusive thrombus in the left anterior descending artery (LAD).
View Article and Find Full Text PDFCost evaluation of acute ischemic stroke in Latin America: a multicentric study.
Lancet Reg Health Am
January 2025
Neurology and Neurosurgery Department Hospital Moinhos de Vento, Porto Alegre, RS, Brazil.
Background: Current literature highlights a gap in precise stroke cost data for Latin America. This study measures the real costs associated with acute ischemic stroke care in Latin America using Time-Driven Activity-Based Costing (TDABC). The findings aim to lay a solid foundation for adopting value-based healthcare (VBHC) strategies in the region.
View Article and Find Full Text PDFInfluence of renal function on blood pressure control and outcome in thrombolyzed patients after acute ischemic stroke: analysis of the ENCHANTED trial.
Front Endocrinol (Lausanne)
December 2024
The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Background: The effect of renal impairment in patients who receive intravenous thrombolysis for acute ischemic stroke (AIS) is unclear. We aimed to determine the associations of renal impairment and clinical outcomes and any modification of the effect of intensive versus guideline-recommended blood pressure (BP) control in the BP arm of the International Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED).
Methods: We conducted a analysis of the ENCHANTED BP arm, which involved 2,196 thrombolyzed AIS patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!